Structural Heart Devices Market Size, Share, and Industry Analysis By Product (Devices (Transcatheter Heart Valves, Surgical Valves) and Accessories), By Procedure (Replacement Procedure and Repair Procedure), By End User (Hospitals & ASCs, Speciality Clinics, and Others), and Regional Forecast, 2026-2034

The global structural heart device market size was valued at USD 18.6 billion in 2025. The market is projected to grow from USD 21.14 billion in 2026 to USD 58.84 billion by 2034, exhibiting a CAGR of 13.65% during the forecast period.

The global structural heart devices market is driven by new transcatheter technology improvements as its main driving force. People choose TAVR more often because doctors install heart valves with catheters rather than open-heart surgery. The structural heart Devices market features medical systems made to fix valves and septa damage that use less invasive techniques instead of open-heart surgery.

As more people reach old age worldwide, there has been a rise in people developing damage to their heart valves, which requires structural treatment. The market for structural heart Devices grows rapidly while specific driving factors force its growth. These two primary factors explain how the industry is expanding rapidly.

Structural Heart Devices Market Driver

Commonness of the disease to Expand the Market

The number of people developing heart structure problems keeps growing and fuels market expansion. The rising number of ageing people globally leads to this growth. As people grow older, their heart valves naturally weaken and produce more conditions such as aortic stenosis and mitral regurgitation.

Advancements in Minimally Invasive Procedures to Advance the Market

Modern technology lets doctors provide better treatment methods for defective heart structures. TAVR fits more patients because it causes less damage to patients while they heal quickly and need fewer precautions.

Structural Heart Devices Market Restraint

High Expenses of Medical Equipment to Pose Potential Impediments on this Market

High expenses of medical equipment and treatment procedures slow down the growth of the structural heart Devices market. People cannot afford to get the medical technology necessary to treat heart diseases, making it tough for doctors to deliver care and stop using these new treatments widely. Complex transcatheter heart valves need advanced engineering parts and specific materials, which make them cost more to create.

Structural Heart Devices Market Opportunity

New Emerging Markets to Create Opportunity in this Market

The market for structural heart Devicess finds substantial growth possibilities through its entry into new emerging markets. The areas that undergo fast healthcare facility development combined with fast middle-class growth experience more heart conditions as people change their habits and age.

Key Insights

The report covers the following key insights:

• Market Drivers, Restraints and Opportunities
• Influence of Key Industrial Players and Key Developments
• Healthcare Expenditure
• Research and Development

Segmentation

Analysis by Product

By product, the structural heart Devices market is divided into Devicess, transcatheter heart valves, surgical valves, and accessories.

The Devicess segment helps treat multiple heart structure problems by making numerous specialised Devicess. Developments in materials and designs stimulate high growth and make heart Devicess more successful and longer-lasting.

The market segment representing Transcatheter Aortic Valve Replacement or Transcatheter Aortic Valve Implantation shows incredible growth. More people are getting aortic stenosis as they become older, which pushes market expansion.

Analysis by Procedure

Based on Procedure, the market is divided into replacement procedure & repair procedure.

The increasing use of TAVR valve implantation procedures fuels the growth of replacement procedures. The heart surgery industry experiences strong expansion because operators now widely choose TAVR over traditional open-heart valve replacement methods.

The Repair Procedure segment performs healing operations to fix broken heart valves instead of replacing them entirely. The market expands because more patients choose structural heart surgeries that keep natural heart systems intact.

Analysis by End User

Based on end user, the market is divided into hospitals & ASCs, speciality clinics, and others.

Hospitals with cardiac catheterisation labs and cardiac surgery units continue to use structural heart Devicess first before all other facilities. Structural heart procedures increase with an ageing population and more heart disorders, leading to market success in these medical facilities. The segment is likely to lead the market.

Structural heart treatment clinics of cardiology and interventional cardiology types grow the market. The market continues to grow because more patients want advanced heart care services provided outside classic hospital walls.

 Regional Analysis

Based on region, the structural heart Devices market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America leads the structural heart Devices sector, and its U.S. market has the strongest presence. The U.S. market shows high embrace of advanced heart treatment technology due to its powerful healthcare system and government support. Heart disease prevalence among an older U.S. population leads to a strong need for structural heart treatments. The U.S. houses primary medical Devices manufacturers who produce and update new healthcare products regularly. FDA requirements help approve new Devicess safely for patient use but still let modern technologies reach patients. The rising number of patients who receive TAVR treatments and the new patient groups who can receive treatment have driven market growth quickly. The U.S. conducts the most medical trials, which supply worldwide information for Devices creation and treatment plans.

• According to the American Heart Association, over 130 million people in the U.S. are projected to be affected by cardiovascular disease by 2035.
• As per the American Heart Association, total direct and indirect costs of cardiovascular disease in the U.S. are expected to exceed USD 1.1 trillion by 2035.

Europe has an advanced and significant market for products that treat heart structure issues. Healthcare delivery systems in this market area vary because of their mix between public and private healthcare funding. Germany, France, and the U.K. support solid cardiology programs, and expert interventional cardiologists help bring forward the newest treatments to their patients. Medical Devicess that receive CE mark approval meet European safety and performance standards, which helps them enter the market. European medical Devices regulations with CE mark approval help Devicess pass safety and performance tests to gain market entry.

The Asia Pacific region shows rapid market expansion for heart structure medical equipment. This part of the world contains different nations that are currently building their healthcare systems quickly as their populations grow. The healthcare industry needs more of these technologies because people today are getting heart problems from new lifestyle choices and as older people become more common. Cardiac care development in Asian countries, especially China, India, and Japan, gets faster as they dedicate more resources to healthcare improvement. The healthcare systems of China, Japan, and India are developing rapidly through invested funds devoted to heart treatment.

Key Players Covered

The report includes the profiles of the following key players:

• Edwards Lifesciences Corporation (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• Teleflex Incorporated (U.S.)
• Integer Holdings Corporation (U.S.)
• Lepu Medical Technology Co.,Ltd. (China)
• Artivion, Inc (U.S.)
• Venus Medtech (China)
• Meril Life Sciences Pvt. Ltd. (China)

Key Industry Developments

• In January 2025, Kestra Medical Technologies and HeartFlow, backed by Bain Capital, started preparing themselves for their turn at the public market with initial public offerings.
• In October 2024, Edwards Lifesciences enhanced their cardiac technology collection with the acquisitions of JenaValve Technology and Endotronix. JenaValve's advanced TAVR systems for treating aortic regurgitation strengthen Edwards' current range of TAVR solutions.